Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: The DEFINE study

Multiple Sclerosis

Volumn 20, Issue 2, 2014, Pages 243-252

  Kappos, Ludwig ^a   Gold, Ralf ^b   Arnold, Douglas L ^c   Bar Or, Amit ^d   Giovannoni, Gavin ^e   Selmaj, Krzysztof ^f   Sarda, Sujata P ^g   Agarwal, Sonalee ^g   Zhang, Annie ^g   Sheikh, Sarah I ^g   Seidman, Emily ^h   Dawson, Katherine T ^g  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b ST JOSEF HOSPITAL   (Germany)

^c NEURORX RESEARCH   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^f MEDICAL UNIVERSITY OF LODZ   (Poland)

^g BIOGEN   (United States)

^h CircleScience   (United Kingdom)

Author keywords

BG 12; DEFINE; dimethyl fumarate; multiple sclerosis; quality of life; randomized controlled trial; relapsing remitting multiple sclerosis

Indexed keywords

FUMARIC ACID DIMETHYL ESTER;

ADULT; ARTICLE; EUROQOL 5D; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; MULTICENTER STUDY (TOPIC); MULTIPLE SCLEROSIS; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT FORM 36; VISUAL ANALOG SCALE; WELLBEING; YOUNG ADULT;

BG-12; DEFINE; DIMETHYL FUMARATE; MULTIPLE SCLEROSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RELAPSING-REMITTING MULTIPLE SCLEROSIS;

ADULT; DOUBLE-BLIND METHOD; FEMALE; FUMARATES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 84893554371     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458513507817     Document Type: Article

References (35)

1. World Health Organisation and Multiple Sclerosis International Federation. Atlas of multiple sclerosis, http://www.atlasofms.org/query.aspx. Published September 2008. AccessedDecember 2012.
2. Nortvedt MW, Riise T. The use of quality of life measures in multiple sclerosis research. Mult Scler. 2003 ; 9: 63-72
3. Miller A, Dishon S. Health-related quality of life in multiple sclerosis: The impact of disability, gender and employment status. Qual Life Res. 2006 ; 15: 259-271
4. Nortvedt MW, Riise T, Myhr KM, et al. Quality of life as a predictor for change in disability in MS. Neurology. 2000 ; 55: 51-54
5. The Goldman Consensus statement on depression in multiple sclerosis. Mult Scler. 2005 ; 11: 328-337
6. Benito-Leon J, Morales JM, Rivera-Navarro J. Health-related quality of life and its relationship to cognitive and emotional functioning in multiple sclerosis patients. Eur J Neurol. 2002 ; 9: 497-502
7. Rudick RA, Miller D, Clough JD, et al. Quality of life in multiple sclerosis. Comparison with inflammatory bowel disease and rheumatoid arthritis. Arch Neurol. 1992 ; 49: 1237-1242
8. Riazi A, Hobart JC, Lamping DL, et al. Using the SF-36 measure to compare the health impact of multiple sclerosis and Parkinson's disease with normal population health profiles. J Neurol Neurosurg Psychiatry. 2003 ; 74: 710-714
9. Linker RA, Lee DH, Ryan S, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain. 2011 ; 134: 678-692
10. Gold R, Kappos L, Arnold DL, et al. Placebo-controlled Phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012 ; 367: 1098-1107
11. Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled Phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012 ; 367: 1087-1097
12. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 Revisions to the "McDonald Criteria.". Ann Neurol. 2005 ; 58: 840-846
13. Ware JE. SF-36 health survey update. Spine. 2000 ; 25: 3130-3139
14. EuroQol - A new facility for the measurement of health-related quality of life. Health Policy. 1990 ; 16: 199-208
15. Rudick RA, Miller D, Hass S, et al. Health-related quality of life in multiple sclerosis: Effects of natalizumab. Ann Neurol. 2007 ; 62: 335-346
16. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation. Med Care. 2003 ; 41: 582-592
17. Ware JE Jr, Gandek B, Kosinski M, et al. The equivalence of SF-36 summary health scores estimated using standard and country-specific algorithms in 10 countries: Results from the International Quality of Life Assessment (IQOLA) Project. J Clin Epidemiol. 1998 ; 51: 1167-1170
18. Miller DM, Weinstock-Guttman B, Bourdette D, et al. Change in quality of life in patients with relapsing-remitting multiple sclerosis over 2 years in relation to other clinical parameters: Results from a trial of intramuscular interferon beta-1a. Mult Scler. 2011 ; 17: 734-742
19. Stephenson JJ, Kern DM, Agarwal SS, et al. Impact of natalizumab on patient-reported outcomes in multiple sclerosis: A longitudinal study. Health Qual Life Outcomes. 2012 ; 10: 155
20. Nortvedt MW, Riise T, Myhr KM, et al. Performance of the SF-36, SF-12, and RAND-36 summary scales in a multiple sclerosis population. Med Care. 2000 ; 38: 1022-1028
21. Menn P, Weber N, Holle R. Health-related quality of life in patients with severe COPD hospitalized for exacerbations - Comparing EQ-5D, SF-12 and SGRQ. Health Qual Life Outcomes. 2010 ; 8: 39
22. Longworth L, Bryan S. An empirical comparison of EQ-5D and SF-6D in liver transplant patients. Health Econ. 2003 ; 12: 1061-1067
23. Speight J, Reaney MD, Barnard KD. Not all roads lead to Rome - A review of quality of life measurement in adults with diabetes. Diabet Med. 2009 ; 26: 315-327
24. Kita M, Fox R, Phillips J, et al. Effect of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: Findings from the CONFIRM study. Mult Scler. 2013 ; X: XX - XX
25. Montalban X, Comi G, O'Connor P, et al. Oral fingolimod (FTY720) in relapsing multiple sclerosis: Impact on health-related quality of life in a Phase II study. Mult Scler. 2011 ; 17: 1341-1350
26. Final appraisal determination - Fingolimod for the treatment of highly active relapsing-remitting multiple sclerosis. National Institute for Health Care and Clinical Excellence. http://www.nice.org.uk/nicemedia/live/12170/58500/ 58500.pdf. Published March 2012. Accessed December 2012.
27. Vermersch P, De SJ, Delisse B, et al. Quality of life in multiple sclerosis: Influence of interferon-beta 1a (Avonex) treatment. Mult Scler. 2002 ; 8: 377-381
28. Zivadinov R, Zorzon M, Tommasi MA, et al. A longitudinal study of quality of life and side effects in patients with multiple sclerosis treated with interferon beta-1a. J Neurol Sci. 2003 ; 216: 113-118
29. Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997 ; 35: 1095-1108
30. MVH Group. The measurement and valuation of health. Final report on the modelling of valuation tariffs, York Centre for Health Economics, UK, http://www.york.ac.uk/media/che/documents/reports/MVH%20Final%20Report.pdf (Published January 1995. Accessed December 2012.
31. Nortvedt MW, Riise T, Myhr KM, et al. Quality of life in multiple sclerosis: Measuring the disease effects more broadly. Neurology. 1999 ; 53: 1098-1103
32. Freeman JA, Hobart JC, Langdon DW, et al. Clinical appropriateness: A key factor in outcome measure selection: The 36-item short form health survey in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2000 ; 68: 150-156
33. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992 ; 30: 473-483
34. Grima DT, Torrance GW, Francis G, et al. Cost and health related quality of life consequences of multiple sclerosis. Mult Scler. 2000 ; 6: 91-98
35. Hobart J, Freeman J, Lamping D, et al. The SF-36 in multiple sclerosis: Why basic assumptions must be tested. J Neurol Neurosurg Psychiatry. 2001 ; 71: 363-370